VALBIOTIS : Release of the Universal Registration Document (R.21-039)

Release of the Universal Registration Document

La Rochelle, July 27, 2021 (9:30 pm CEST) - Valbiotis (FR0013254851 - ALVAL, eligible for the PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, has informed the public that its Universal Registration Document was approved by the French Financial Markets Regulator (AMF) on July 27, 2021 under the number R.21-039.

This document is available to the public free of charge under the conditions laid down in the regulations in force, and can be consulted and downloaded from both the Valbiotis website (https://www.valbiotis.com/en/regulatory-information/) and the AMF website (www.amf-france.org/).

The document presents the highlights and financial information for the year ended December 31, 2020 in addition to key events since January 1, 2021, including the publication of the first scientific articles on TOTUM•63 in three international journals (press release of June 3, 2021), the changes to the Company's Board of Directors with the appointment of Sébastien Bessy (press release of June 7, 2021), and the updated cash position following the capital increase completed in April 2021 (press release of April 15, 2021).

The Company can rely on this strengthened and sustainable financial structure to accelerate the development of its research programs on the reduction of LDL cholesterol (TOTUM•070) and the reduction of blood pressure (TOTUM•854), while continuing the final stages of development of TOTUM•63 financed by Nestlé Health Science.

Valbiotis will publish its half-yearly results on Thursday September 30, 2021.

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health sector.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63) - and has a subsidiary in Quebec City (Canada).

Valbiotis is a member of the «BPI Excellence» network and has been recognized as an «Innovative Company» by the BPI label. Valbiotis has also been awarded «Young Innovative Company» status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: www.valbiotis.com

Press release

Contacts

Corporate communication / Valbiotis	Financial communication / Actifin
Carole ROCHER / Marc DELAUNAY	Stéphane RUIZ
[phone]	[phone]
[e-mail]	[e-mail]

Name: Valbiotis

ISIN code: FR0013254851

Mnemonic code: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, filed with the French Financial Markets Regulator (AMF) on 27 July 2021 (application number R.21-039). This document is available on the Company's website (www.valbiotis.com).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.

Press release